Pharma industry urges White House to allow patent protections for COVID-19 products

Pharmaceutical lobby PhRMA sent a letter March 5 to President Joe Biden urging him to reject a proposal that would temporarily waive patent rights for COVID-19 products.

The group said that pharmaceutical companies' intellectual property protections won't prevent COVID-19 treatments and prophylactics from being globally available. It also said that such protections expedite the development of new COVID-19 products and help companies better share their technology and information to increase manufacturing.

"Eliminating those protections would undermine the global response to the pandemic, including ongoing effort to tackle new variants, create confusion that could potentially undermine public confidence in vaccine safety, and create a barrier to information sharing," PhRMA wrote. "Most importantly, eliminating protections would not speed up production."

More articles on pharmacy:
Pfizer vaccine 95% effective against coronavirus variant found in Brazil, small study shows
Detroit mayor declines J&J vaccine shipment, but says 'each vaccine is safe'
3 top trends for the pharmacy industry in 2021 from CVS Health report



Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars